Isomorphic Labs

Alphabet's Isomorphic Labs raised $2.1 billion in funding to advance AI drug discovery toward clinical trials. This massive investment signals growing confidence in AI's ability to accelerate pharmaceutical development, potentially reducing the traditional 10-15 year drug development timeline.

Isomorphic Labs, a DeepMind spinoff, has built a pipeline of AI-designed medicines headed to human trials. This milestone represents the first major transition of AI-discovered drugs from laboratory to clinical testing, potentially accelerating pharmaceutical development timelines.